Page 71 - Binder2
P. 71
In many therapeutic areas, the top-selling biologics are
clustered within a handful of mechanisms—anti-TNF, anti-
IL-6, anti-CD20. These drugs are often owned or co-
marketed by the same few pharmaceutical giants. When
one fails, and the patient moves to another, the money stays
in-house. From the industry’s perspective, tolerization
isn’t a market failure. It’s a patient progression path.
69
